* Flerie has proposed a merger with Lipum * Topline data support BSSL’s role in RA * Our model suggests a fair value of SEK 16.29 per share A key issue in Lipum’s preparations for the anticipated phase II study has been the financing. This will now likely...

Lipum

Lehdistötiedote28.11.2025 klo 9.03

Västra Hamnen Market Focus: Lipum: Merging with Flerie

Lipum

Lehdistötiedote27.11.2025 klo 13.08

Redeye: Lipum (Q3 review) - Going private

Lipum

Lehdistötiedote27.11.2025 klo 11.19

BioStock: Lipum steps up ahead of phase II – clear signals in Q3

Lipum

Pörssitiedote27.11.2025 klo 7.00

Lipum AB – interim report Q3 for the period July-September 2025

Lipum

Lehdistötiedote20.11.2025 klo 10.38

BioStock: Lipum’s CEO on the merger with Flerie and the path toward phase II

Lipum

Pörssitiedote18.11.2025 klo 7.02

STATEMENT BY THE BOARD OF DIRECTORS OF LIPUM IN VIEW OF THE MERGER OFFER BY FLERIE

Lipum

Pörssitiedote18.11.2025 klo 7.00

Flerie and Lipum have agreed on a merger plan

Lipum

Lehdistötiedote30.10.2025 klo 7.30

Lipum presents new topline data supporting BSSL’s role in rheumatoid arthritis

Lipum

Lehdistötiedote7.10.2025 klo 7.07

BioStock: Lipum gears up with new CFO – one month into the assignment

Lipum

Lehdistötiedote25.9.2025 klo 9.48

BioStock: Video from Lipum’s live interview at BioStock Investing in Life Science – From Seed to Success

Lipum

Kolmannen osapuolen analyysi1.9.2025 klo 11.01

Lipum: Finding financial support - VH Corp

* Preparations progress as planned * Loan facilities provide support for 2025 * Our model suggests a fair value of SEK 16.29 per share Lipum reported in its Q2 report that the manufacturing process of SOL-116 is nearing the final phase. The drug candidate...

Lipum

Lehdistötiedote1.9.2025 klo 11.00

Lipum

The merger between Flerie and Lipum has been completed

The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum

Lipum selected for Horizon Europe grant

Liity Inderesin yhteisöön

FREE-tili

PREMIUM-tili

Redeye: Lipum (Q4 Reviev): Approaching merger completion

Lipum AB – Year-end report 2025

Lipum: Merging with Flerie - VH Corp

Västra Hamnen Market Focus: Lipum: Merging with Flerie

Redeye: Lipum (Q3 review) - Going private

BioStock: Lipum steps up ahead of phase II – clear signals in Q3

Lipum AB – interim report Q3 for the period July-September 2025

BioStock: Lipum’s CEO on the merger with Flerie and the path toward phase II

STATEMENT BY THE BOARD OF DIRECTORS OF LIPUM IN VIEW OF THE MERGER OFFER BY FLERIE

Flerie and Lipum have agreed on a merger plan

Lipum presents new topline data supporting BSSL’s role in rheumatoid arthritis

BioStock: Lipum gears up with new CFO – one month into the assignment

BioStock: Video from Lipum’s live interview at BioStock Investing in Life Science – From Seed to Success

Lipum: Finding financial support - VH Corp

Västra Hamnen Market Focus: Lipum: Finding financial support

BioStock: Focus on preparation for Lipum during Q2

Redeye: Lipum Q2 - Focus on securing funding